Poster Tour 3: Clinical
Tracks
Track 1
Track 2
| Thursday, September 12, 2019 |
| 3:10 PM - 3:40 PM |
| Level 8 |
Speaker
Ms. Tianna Magel
Research Associate
Vancouver Infectious Diseases Centre
#054 MORBIDITY AND MORTALITY IN HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD): BEYOND THE SVR12
3:10 PM - 3:15 PMBiography
Tianna received her degree from the University of British Columbia. She currently works as a research assistant at Vancouver Infectious Diseases Centre, where she researches HCV/HIV in vulnerable populations.
Dr. Valérie Martel-laferrière
Physician
CHUM
#055 EFFECT OF A SINGLE-DAY INVESTIGATION FOR HCV INFECTION ON TREATMENT INITIATION AMONG PWID, BEFORE AND AFTER UNIVERSAL ACCESS TO DIRECT ACTING ANTIVIRALS
3:15 PM - 3:20 PMBiography
Valérie Martel-Laferrière is an infectious disease and medical microbiologist at the University of Montreal hospital center and a researcher at the University of Montreal. Her research interests focus on hepatitis C screening and treatment among vulnerable population, especially persons who use drugs and HIV-HCV co-infected patients.
Mr Christian Sharkey
Specialist Nurse
NHS Tayside
#058 WORKING TOWARDS MICRO-ELIMINATION OF HCV IN PWID. A DIRECT OBSERVED THERAPY VS FORTNIGHTLY COLLECTION STUDY FOR HCV TREATMENT – ADVANCE HCV STUDY
3:20 PM - 3:25 PMBiography
Christian Sharkey is a Specialist Nurse supporting recruitment of participants to the HCV clinical trial ADVANCE.
ADVANCE is a 2-year randomised, un-blinded trial which explores feasibility and efficacy of treating PWID by nurses embedded within injecting equipment provision sites across Tayside, Scotland.
Dr. Jeffrey Weiss
Associate Professor
Icahn School Of Medicine At Mount Sinai
#059 Randomized Clinical Trial to Test E-health Interventions to Improve Adherence to a Once-daily Single-tablet Regimen in Patients with Chronic Hepatitis C Virus Infection
3:25 PM - 3:30 PMBiography
Jeffrey J. Weiss, PhD, MS, is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the Director of the Respectful & Equitable Access to Comprehensive Healthcare (REACH) Program in the Division of General Internal Medicine.
Ms. Kate Mason
Researcher
Toronto Community Hep C Program
#057 Feasibility of rapid hepatitis C point-of-care RNA testing and treatment at an integrated supervised consumption site in Toronto, Canada
3:30 PM - 3:35 PMBiography
Kate Mason is a community-based researcher with a focus on work related to poverty, substance use and health. She currently works with the Toronto Community Hep C Program.
Chair
Margaret Hellard
Program Director
Burnet Institute
